par Karras, Panagiotis 
;Riveiro-Falkenbach, Erica;Cañón, Estela;Tejedo, Cristina;Calvo, Tonantzin T.G.;Martínez-Herranz, Raúl;Alonso-Curbelo, Direna;Cifdaloz, Metehan;Perez-Guijarro, Eva;Gómez-López, Gonzalo;Ximenez-Embun, Pilar;Muñoz, Javier;Megías, Diego;Olmeda, David;Moscat, Jorge;Ortiz-Romero, Pablo Luis;Rodríguez-Peralto, José Luis;Soengas, María M.S.
Référence Cancer cell, 35, 1, page (46-63.e10)
Publication Publié, 2019-01-01
;Riveiro-Falkenbach, Erica;Cañón, Estela;Tejedo, Cristina;Calvo, Tonantzin T.G.;Martínez-Herranz, Raúl;Alonso-Curbelo, Direna;Cifdaloz, Metehan;Perez-Guijarro, Eva;Gómez-López, Gonzalo;Ximenez-Embun, Pilar;Muñoz, Javier;Megías, Diego;Olmeda, David;Moscat, Jorge;Ortiz-Romero, Pablo Luis;Rodríguez-Peralto, José Luis;Soengas, María M.S.Référence Cancer cell, 35, 1, page (46-63.e10)
Publication Publié, 2019-01-01
Article révisé par les pairs
| Résumé : | Modulators of mRNA stability are not well understood in melanoma, an aggressive tumor with complex changes in the transcriptome. Here we report the ability of p62/SQSTM1 to extend mRNA half-life of a spectrum of pro-metastatic factors. These include FERMT2 and other transcripts with no previous links to melanoma. Transcriptomic, proteomic, and interactomic analyses, combined with validation in clinical biopsies and mouse models, identified a selected set of RNA-binding proteins (RBPs) recruited by p62, with IGF2BP1 as a key partner. This p62-RBP interaction distinguishes melanoma from other tumors where p62 controls autophagy or oxidative stress. The relevance of these data is emphasized by follow-up analyses of patient prognosis revealing p62 and FERMT2 as adverse determinants of disease-free survival. |
